LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 37

Search options

  1. Article ; Online: Effect of L-Methylfolate Supplementation on Sleep for Patients with Reduced Methylenetetrahydrofolate Reductase Activity.

    Carmon, Alex S / Amato, Russell J / Patel, Seema M / Finks, Shannon W

    Journal of dietary supplements

    2024  , Page(s) 1–9

    Abstract: Introduction: Clinicians have limited options outside controlled substances to address sleep disturbance, which left untreated can negatively affect patient outcomes in cardiovascular health, mental health, immunologic function, and more. For some, ... ...

    Abstract Introduction: Clinicians have limited options outside controlled substances to address sleep disturbance, which left untreated can negatively affect patient outcomes in cardiovascular health, mental health, immunologic function, and more. For some, genetic factors may influence sleep disturbances. L-methylfolate, the active form of folate, plays a critical role in regulation of monoamine neurotransmitters known to have significant impact on sleep regulation: dopamine, serotonin, norepinephrine. Single nucleotide polymorphisms of the enzyme methylene-tetrahydrofolate-reductase are common and can impact monoamine production. The goal of this study was to evaluate effects of L-methylfolate supplementation on sleep in a cohort with reduced methylene tetrahydrofolate reductase (MTHFR) activity.
    Methods: A retrospective cohort of patients being treated with L-methylfolate in a concierge medical clinic setting was studied. Patients presenting with sleep complaints were evaluated using the Patient-Reported Outcomes Measurement Information System at baseline. Patients with known MTHFR polymorphisms at either C667T and/or A1298C were recommended 5 mg of L-methylfolate daily and were reevaluated at 2 wks, at 4 wks, and at 8 wks of supplementation. Statistical comparisons were made utilizing ANOVA and T-test comparisons.
    Results: Ten were included in the final cohort: six male and four female, average age 43 ± 16 years. Beginning at wk 2, average sleep disturbance improved significantly by -6.94 points (
    Conclusion: Improvement in sleep disturbance was seen in both low and intermediate function phenotypes. L-methylfolate may be useful for improving sleep in patients with MTHFR polymorphism.
    Language English
    Publishing date 2024-03-25
    Publishing country England
    Document type Journal Article
    ZDB-ID 2460305-3
    ISSN 1939-022X ; 1939-0211
    ISSN (online) 1939-022X
    ISSN 1939-0211
    DOI 10.1080/19390211.2024.2327541
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Bonn / Germany

    Z 6537: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  2. Article ; Online: Hypertension in Chronic Obstructive Pulmonary Disease. Reply.

    Finks, Shannon W / Rumbak, Mark J / Self, Timothy H

    The New England journal of medicine

    2020  Volume 382, Issue 17, Page(s) 1674

    MeSH term(s) Humans ; Hypertension ; Pulmonary Disease, Chronic Obstructive
    Language English
    Publishing date 2020-04-22
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 207154-x
    ISSN 1533-4406 ; 0028-4793
    ISSN (online) 1533-4406
    ISSN 0028-4793
    DOI 10.1056/NEJMc2003536
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ua VI Zs.34: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Treating Hypertension in Chronic Obstructive Pulmonary Disease.

    Finks, Shannon W / Rumbak, Mark J / Self, Timothy H

    The New England journal of medicine

    2020  Volume 382, Issue 4, Page(s) 353–363

    MeSH term(s) Angiotensin Receptor Antagonists/therapeutic use ; Angiotensin-Converting Enzyme Inhibitors/therapeutic use ; Antihypertensive Agents/therapeutic use ; Humans ; Hypertension/complications ; Hypertension/diagnosis ; Hypertension/drug therapy ; Pulmonary Disease, Chronic Obstructive/complications
    Chemical Substances Angiotensin Receptor Antagonists ; Angiotensin-Converting Enzyme Inhibitors ; Antihypertensive Agents
    Language English
    Publishing date 2020-01-23
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 207154-x
    ISSN 1533-4406 ; 0028-4793
    ISSN (online) 1533-4406
    ISSN 0028-4793
    DOI 10.1056/NEJMra1805377
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ua VI Zs.34: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Idarucizumab (Praxbind): The First Reversal Agent for a Direct Oral Anticoagulant.

    Finks, Shannon W / Rogers, Kelly C

    The American journal of medicine

    2017  Volume 130, Issue 5, Page(s) e195–e197

    Language English
    Publishing date 2017-05
    Publishing country United States
    Document type Editorial
    ZDB-ID 80015-6
    ISSN 1555-7162 ; 1873-2178 ; 0002-9343 ; 1548-2766
    ISSN (online) 1555-7162 ; 1873-2178
    ISSN 0002-9343 ; 1548-2766
    DOI 10.1016/j.amjmed.2016.11.029
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ua VI Zs.289: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: A New Option for Reversing the Anticoagulant Effect of Factor Xa Inhibitors: Andexanet Alfa (ANDEXXA).

    Rogers, Kelly C / Finks, Shannon W

    The American journal of medicine

    2018  Volume 132, Issue 1, Page(s) 38–41

    Abstract: The use of direct oral anticoagulants over traditional warfarin has increased in the United States over the past 10 years because of advantages such as ease of use, predictable pharmacokinetic response, and safety. In 2015, the U.S. Food and Drug ... ...

    Abstract The use of direct oral anticoagulants over traditional warfarin has increased in the United States over the past 10 years because of advantages such as ease of use, predictable pharmacokinetic response, and safety. In 2015, the U.S. Food and Drug Administration approved idarucizumab (Praxbind) for the reversal of the direct thrombin inhibitor dabigatran, but no reversal agent has been available for oral factor Xa (FXa) inhibitors until recently. Andexanet alfa was approved in May 2018, under the brand name ANDEXXA, for the reversal of 2 of FXa inhibitors, apixaban and rivaroxaban, when life-threatening or uncontrolled bleeding occurs. This accelerated approval was based on change in anti-FXa activity from baseline that indicated a reversal of the anticoagulant effect. Any expanded Food and Drug Administration indication will be contingent on results demonstrating improved hemostasis and efficacy for reversing other FXa inhibitors.
    MeSH term(s) Antidotes ; Factor Xa/pharmacology ; Factor Xa/therapeutic use ; Factor Xa Inhibitors ; Hemorrhage/chemically induced ; Hemorrhage/drug therapy ; Humans ; Recombinant Proteins/pharmacology ; Recombinant Proteins/therapeutic use
    Chemical Substances Antidotes ; Factor Xa Inhibitors ; PRT064445 ; Recombinant Proteins ; Factor Xa (EC 3.4.21.6)
    Language English
    Publishing date 2018-07-25
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 80015-6
    ISSN 1555-7162 ; 1873-2178 ; 0002-9343 ; 1548-2766
    ISSN (online) 1555-7162 ; 1873-2178
    ISSN 0002-9343 ; 1548-2766
    DOI 10.1016/j.amjmed.2018.06.028
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ua VI Zs.289: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Dual Antiplatelet Therapy for Long-term Secondary Prevention of Atherosclerotic Cardiovascular Events.

    Dobesh, Paul P / Finks, Shannon W / Trujillo, Toby C

    Clinical therapeutics

    2020  Volume 42, Issue 10, Page(s) 2084–2097

    Abstract: Purpose: Dual antiplatelet therapy (DAPT) with aspirin and a P2Y: Methods: A search of PubMed was performed to identify articles published in the last 20 years that addressed the role of DAPT beyond 12 months' duration.: Findings: A number of ... ...

    Abstract Purpose: Dual antiplatelet therapy (DAPT) with aspirin and a P2Y
    Methods: A search of PubMed was performed to identify articles published in the last 20 years that addressed the role of DAPT beyond 12 months' duration.
    Findings: A number of studies have shown ischemic benefits associated with prolonging DAPT beyond 12 months, but this finding is dependent on the patient population studied and the quality of the study design. Many studies also show that longer duration therapy has been associated with increased bleeding risk. In patients with previous myocardial infarction completing at least 1 year of DAPT, continuing DAPT with a reduced dose of ticagrelor 60 mg BID is a regimen to be considered for these patients; in general ACS patients, a reduced dose of 60 mg BID of ticagrelor after the first year of DAPT should be considered; and in the post-percutaneous coronary intervention patients, DAPT beyond 1 year should be considered after careful evaluation of the patient's thrombotic and bleeding risks.
    Implications: The duration of DAPT, and the choice of P2Y
    MeSH term(s) Acute Coronary Syndrome/drug therapy ; Aspirin/therapeutic use ; Drug Therapy, Combination ; Drug-Eluting Stents/adverse effects ; Hemorrhage/epidemiology ; Humans ; Myocardial Infarction/drug therapy ; Percutaneous Coronary Intervention/methods ; Platelet Aggregation Inhibitors/administration & dosage ; Platelet Aggregation Inhibitors/therapeutic use ; Risk Factors ; Secondary Prevention ; Thrombosis/prevention & control ; Ticagrelor/therapeutic use ; Time Factors
    Chemical Substances Platelet Aggregation Inhibitors ; Ticagrelor (GLH0314RVC) ; Aspirin (R16CO5Y76E)
    Language English
    Publishing date 2020-08-29
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 603113-4
    ISSN 1879-114X ; 0149-2918
    ISSN (online) 1879-114X
    ISSN 0149-2918
    DOI 10.1016/j.clinthera.2020.08.003
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1435: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 404: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Edoxaban: How Does the Newest Agent Fit into the DOAC Landscape?

    Gibson, Caitlin M / Finks, Shannon W

    The American journal of medicine

    2017  Volume 130, Issue 8, Page(s) 900–906

    Abstract: Edoxaban is the most recently approved factor Xa inhibitor within the class of direct oral anticoagulants (DOACs). Like other DOACs, edoxaban was approved by the US Food and Drug Administration for treatment of venous thromboembolism and prevention of ... ...

    Abstract Edoxaban is the most recently approved factor Xa inhibitor within the class of direct oral anticoagulants (DOACs). Like other DOACs, edoxaban was approved by the US Food and Drug Administration for treatment of venous thromboembolism and prevention of stroke in patients with nonvalvular atrial fibrillation. Similar to other DOACs, edoxaban has fewer drug-drug interactions than warfarin and does not require routine laboratory monitoring. Unlike other DOACs, edoxaban has yet to be approved for secondary or postoperative venous thromboembolism thromboprophylaxis. Currently no antidote for edoxaban is available. To optimally prescribe agents in the DOAC class, it is critical that providers 1) understand how the agents compare; and 2) identify specific settings in which one agent may be preferred over another.
    MeSH term(s) Administration, Oral ; Factor Xa Inhibitors/administration & dosage ; Factor Xa Inhibitors/pharmacology ; Factor Xa Inhibitors/therapeutic use ; Humans ; Pyridines/administration & dosage ; Pyridines/pharmacology ; Pyridines/therapeutic use ; Thiazoles/administration & dosage ; Thiazoles/pharmacology ; Thiazoles/therapeutic use ; Venous Thromboembolism/drug therapy ; Venous Thromboembolism/prevention & control
    Chemical Substances Factor Xa Inhibitors ; Pyridines ; Thiazoles ; edoxaban (NDU3J18APO)
    Language English
    Publishing date 2017-04-06
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 80015-6
    ISSN 1555-7162 ; 1873-2178 ; 0002-9343 ; 1548-2766
    ISSN (online) 1555-7162 ; 1873-2178
    ISSN 0002-9343 ; 1548-2766
    DOI 10.1016/j.amjmed.2017.02.048
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ua VI Zs.289: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article: Medication Optimization: Integration of Comprehensive Medication Management into Practice.

    McFarland, M Shawn / Finks, Shannon W / Smith, Lisa / Buck, Marcia L / Ourth, Heather / Brummel, Amanda

    American health & drug benefits

    2021  Volume 14, Issue 3, Page(s) 111–114

    Language English
    Publishing date 2021-09-25
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2853721-X
    ISSN 1942-2970 ; 1942-2962
    ISSN (online) 1942-2970
    ISSN 1942-2962
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article: Duration of triple antithrombotic therapy and outcomes among patients undergoing percutaneous coronary intervention.

    Shah, Rahman / Delgado, Glenda / Finks, Shannon W

    Cardiovascular diagnosis and therapy

    2017  Volume 7, Issue Suppl 2, Page(s) S66–S68

    Language English
    Publishing date 2017-07-15
    Publishing country China (Republic : 1949- )
    Document type Editorial ; Comment
    ZDB-ID 2685043-6
    ISSN 2223-3660 ; 2223-3652
    ISSN (online) 2223-3660
    ISSN 2223-3652
    DOI 10.21037/cdt.2016.11.07
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Contemporary Management of Direct Oral Anticoagulants During Cardioversion and Ablation for Nonvalvular Atrial Fibrillation.

    Trujillo, Toby C / Dobesh, Paul P / Crossley, George H / Finks, Shannon W

    Pharmacotherapy

    2019  Volume 39, Issue 1, Page(s) 94–108

    Abstract: As overall prevalence of atrial fibrillation (AF) continues to rise, the number of patients who undergo ablation, or electrical/chemical cardioversion, to restore normal sinus rhythm continues to increase as well. As direct oral anticoagulants (DOACs) ... ...

    Abstract As overall prevalence of atrial fibrillation (AF) continues to rise, the number of patients who undergo ablation, or electrical/chemical cardioversion, to restore normal sinus rhythm continues to increase as well. As direct oral anticoagulants (DOACs) have continued to be incorporated into clinical practice for long-term anticoagulation for AF, experience with how best to manage use of DOACs during electrophysiologic procedures is evolving. This review is intended to provide health care providers with a summary of current evidence regarding the use of DOACs during cardioversion and catheter ablation and provide key considerations for their use during such electrophysiologic procedures. PubMed and MEDLINE were searched from inception through June 2018 for studies in humans comparing DOACs alone or against vitamin K antagonists (VKAs) in adult patients (> 18 yrs) who underwent cardioversion or AF catheter ablation using the following key words: "rivaroxaban," "dabigatran," "apixaban," "edoxaban," "non-vitamin K antagonists," "direct or new oral anticoagulants," "warfarin," "vitamin K antagonists," "cardioversion," "ablation of atrial fibrillation," "uninterrupted," and "catheter ablation." Four retrospective studies and three prospective trials comparing DOACs with VKA in patients undergoing cardioversion and three prospective studies in patients undergoing catheter ablation for AF were identified. Observational data and meta-analyses were also critically reviewed. Prospective trials to date suggest similar efficacy and safety with using DOACs in the setting of cardioversion and AF ablation compared to traditional therapy with VKA, with or without bridging. Injectable anticoagulant overlap can be avoided in patients receiving DOACs in the setting of cardioversion for AF. Minimal interruption in anticoagulation may be only necessary for AF ablation in those with highest bleeding risk, such as in renal dysfunction and where drug-drug interactions may increase risk for anticoagulant accumulation. Periprocedural advantages of DOACs include convenience, rapid and predictable onset of effect, improved patient satisfaction, and potential for reduced costs.
    MeSH term(s) Administration, Oral ; Adult ; Anticoagulants/administration & dosage ; Anticoagulants/adverse effects ; Atrial Fibrillation/therapy ; Catheter Ablation/methods ; Electric Countershock/methods ; Humans ; Vitamin K/antagonists & inhibitors
    Chemical Substances Anticoagulants ; Vitamin K (12001-79-5)
    Language English
    Publishing date 2019-01-11
    Publishing country United States
    Document type Comparative Study ; Journal Article ; Review
    ZDB-ID 603158-4
    ISSN 1875-9114 ; 0277-0008
    ISSN (online) 1875-9114
    ISSN 0277-0008
    DOI 10.1002/phar.2205
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1738: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 585: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top